:
The rising prevalence of urea cycle disorders is expected to increase the demand for treatment options for urea cycle disorders (UCD), which is expected to drive the growth of global urea cycle disorders treatment market during the forecast period. According to the Urea Cycle Disorders Consortium (UCDC), a part of the Rare Diseases Clinical Research Network (RDCRN), combined prevalence of urea cycle disorders is around 1 in 30,000 people in the U.S in 2017
Among regions, North America is expected to hold dominant position in the global urea cycle disorders treatment market during the forecast period, owing to key companies focusing on product launches for the treatment of Urea cycle disorders. For instance, in January 2021, Recordati Rare Diseases Inc. received the U.S. Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia.
Bausch Health Announces Participation At The Jefferies Healthcare Conference
Bausch Health Companies Inc. today announced that Joseph C. Papa chairman and chief executive officer; Sam Eldessouky senior vice president and corporate controller; and Arthur J. Shannon senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Jefferies Healthcare Conference on June 2, 2021 at 11:00 a.m. ET . A live webcast and audio archive of the events will be …
Bausch Health Companies Inc. (NYSETSX: BHC) (“Bausch Health” or the “Company”) today announced that Joseph C. Papa chairman and chief executive officer; Sam Eldessouky senior vice president and corporate controller; and Arthur J. Shannon senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Jefferies Healthcare Conference on June 2, 2021 at 11:00 a.m. ET .
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
Bausch Health Companies Inc. announced today that it has priced its previously announced offering of $1.6 billion aggregate principal amount of 4.875% senior secured notes due 2028 . The Notes will be sold to investors at a price of 100% of the principal amount thereof. The proceeds from the offering of the Notes, along with cash on hand, are expected to be used to fund the Company’s offer to purchase any and all of …
Bausch Health Companies Inc. (NYSETSX: BHC) (“Bausch Health” or the “Company”) announced today that it has priced its previously announced offering of $1.6 billion aggregate principal amount of 4.875% senior secured notes due 2028 (the “Notes”). The Notes will be sold to investors at a price of 100% of the principal amount thereof. The proceeds from the offering of the Notes, along with cash on hand, are expected to be used to fund the Company’s offer to purchase (the “Tend
Bausch Health Companies Inc. announced today that it has commenced a cash tender offer to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 . The terms and conditions of the Tender Offer are described in an Offer to Purchase dated May 24 2021 . The following table sets forth certain terms of the Tender Offer: The Tender Offer will expire at 11:59 p.m. New York City time, on June 21, .